alovudine has been researched along with Pancreatic Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abt, ER; Carlucci, G; Cho, A; Creech, AL; Cui, J; Czernin, J; Dann, AM; Donahue, TR; Ghukasyan, R; Le, TM; Li, L; Liang, K; Radu, CG; Rashid, K; Rosser, EW; Wei, L; Wu, N | 1 |
| Fujimoto, K; Mitamura, K; Nishiyama, Y; Norikane, T; Okano, K; Suzuki, Y; Yamamoto, Y | 1 |
| Aboagye, EO; Barwick, T; Challapalli, A; Howell, EC; Mauri, F; Maxwell, RJ; Merchant, S; Pearson, RA; Sharma, R; Sumpter, K | 1 |
| Dahlman, A; Fröhlich, C; Horak, ID; Jacobsen, HJ; Jensen, MM; Kjaer, A; Kragh, M; Kristensen, LK; Lantto, J; Nielsen, CH; Poulsen, TT | 1 |
| Cieslak, JA; Cullen, JJ; Du, J; Ponto, LL; Sibenaller, ZA; Sunderland, JJ; Walsh, SA | 1 |
| Cass, CE; Paproski, RJ; Young, JD | 1 |
| Billotey, C; Borson-Chazot, F; Bournaud, C; Cornu, C; Giammarile, F; Hervieu, V; Houzard, C; Janier, M; Le Bars, D; Lombard-Bohas, C; Masson, S; Scoazec, JY; Vuillez, JP; Walter, T | 1 |
| Beer, AJ; Buck, AK; Dobritz, M; Erkan, M; Friess, H; Herrmann, K; Kleeff, J; Schmid, RM; Schuster, T; Schwaiger, M; Siveke, JT; Wester, HJ | 1 |
| Glatting, G; Leder, G; Neumaier, B; Reske, SN; Schmid, RM; Seitz, U; Wagner, M; Wawra, E | 1 |
| Chang, ST; Chin, F; Dick, DW; Gambhir, SS; Kamaya, A; Koong, AC; Loo, BW; Quon, A | 1 |
1 trial(s) available for alovudine and Pancreatic Neoplasms
| Article | Year |
|---|---|
18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Topics: Adult; Aged; Cell Differentiation; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2011 |
9 other study(ies) available for alovudine and Pancreatic Neoplasms
| Article | Year |
|---|---|
STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [
Topics: Animals; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorine Radioisotopes; Humans; Interferon Type I; Male; Membrane Proteins; Mice; Mice, Inbred NOD; Pancreatic Neoplasms; Positron-Emission Tomography; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Liver Abscess With High 18F-FDG Uptake and No 18F-Fluorothymidine Uptake.
Topics: Biological Transport; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Liver Abscess; Male; Middle Aged; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Receptor, ErbB-2; Receptor, ErbB-3; Time Factors; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Dideoxynucleosides; Drug Monitoring; Humans; Isotope Labeling; Metabolic Clearance Rate; Mice; Mice, Nude; Pancreatic Neoplasms; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2016 |
Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine.
Topics: Biological Transport; Cell Line, Tumor; Deoxycytidine; Dideoxynucleosides; Fluorine Radioisotopes; Gemcitabine; Humans; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Protein Binding | 2010 |
Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Contrast Media; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines.
Topics: Base Sequence; Biological Transport; Chronic Disease; Dideoxynucleosides; Fluorine Radioisotopes; Humans; Pancreatic Neoplasms; Pancreatitis; Polymerase Chain Reaction; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; RNA, Neoplasm; Tumor Cells, Cultured | 2002 |
Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Dideoxynucleosides; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2008 |